BRCA2 and prostate cancer: Our data confirmed that shRNA mediated stable knockdown of well-known HR genes BRCA2/ATM in a prostate cancer cell line model led to 8- to 12-fold increased sensitivity toward LP-184, as compared with only 2- to 8-fold increased sensitivity toward olaparib.